Koh KK, et al. - Alirocumab was assessed for efficacy and safety in South Korean and Taiwanese patients enrolled in ODYSSEY KT. Findings demonstrated that Asian patients consuming alirocumab exhibited significant improvements in low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, non-high-density lipoprotein cholesterol (non-HDL-C), lipoprotein (a) [Lp(a)], HDL-C and total cholesterol. Furthermore, study participants generally well-tolerated alirocumab. These findings are consistent with ODYSSEY findings to date.